SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMPs decline and persistent losses are driving discussion, with many traders calling the politically branded memecoin a scam or rug pull and lamenting their holdings. Some supporters expect a rebound or short squeeze, but those views are speculative.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp selloff and break below a key psychological support level dominate discussion, with traders pointing to heavy selling and leveraged long liquidations. The community is split between expecting further losses and viewing the dip as a potential bear trap or buying opportunity.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSkys expanded seven-figure Gen-3 Assured contract with an international defense partner is drawing attention, with traders viewing the customer expansion as positive but questioning why the stocks reaction has been muted. Some also point to Rocket Lab as a potential launch partner, though that is speculation.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas weakness and fresh 52-week lows are attributed by bearish traders to warmer weather expectations and surplus inventories. Some investors are buying the dip or positioning for winter demand, but the community remains divided on whether a seasonal rebound will materialize.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoins sharp swings and reported leveraged-position liquidations dominate the discussion, with bearish traders warning of further downside while bulls point to rebounds and renewed ETF demand. Macro conditions and crypto-regulation developments are also cited as potential influences, but sentiment remains divided.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Cantons institutional-adoption storyespecially DTCC tokenization plans and Visa joining the network as a super validatoris driving attention. Bulls see growing use for real-world asset infrastructure, while skeptics question whether that adoption will lift CCs price amid token issuance and unlocks.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

Northlands upgrade of C3.ai, citing its C3 Code platform for building agentic AI applications, is fueling bullish interest alongside discussion of a technical rebound and possible short covering. Skeptics counter that declining revenue and weak fundamentals make the rally difficult to trust.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is drawing attention for strong QNX momentum, including a record royalty backlog, its major Alloy Kore design win, and an Uber selection for a next-generation vehicle platform; the company also beat earnings expectations and raised its outlook. Bulls see these developments as evidence of growth in automotive software and physical AI, while skeptics question how quickly design wins will translate into revenue and point to volatile post-news trading.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Discussion is focused on claims that NEAR used DFINITY/ICP cryptographic technology, with traders speculating about possible legal action; the allegations are not established as fact. That debate is adding to an ongoing argument over ICPs weak price performance and whether its technology and adoption prospects can catch up with NEAR.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3Ms quarterly earnings beat and higher full-year outlook, alongside its expanded Amazon data-center partnership, are driving attention. Bulls see evidence of a turnaround and AI-infrastructure opportunity, while skeptics note Amazons purchases are not guaranteed under the warrant arrangement and are betting the news-driven gains may fade.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNTechs oncology pipeline is under scrutiny after its BNT113 cancer trial missed a key progression-free-survival endpoint, while the ongoing leadership transition and weak revenue outlook add to investor concerns. Bulls argue the companys cash reserves and other late-stage cancer programs still offer potential, but skeptics question whether the pipeline can deliver.

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings 

Equity

Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.

Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch

Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.

BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)

BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)PR NewswireNEW YORK, Oct. 14, 2026BioNTech investors absorbed a 7.13% loss when the...

BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles

BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock. 


BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’

BioNTech’s experimental cancer treatment combined with Merck’s Keytruda failed to significantly delay disease progression compared with Keytruda alone.


MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?

Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push 

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.


Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?

Moderna (NASDAQ: MRNA) has delivered the pivotal cancer result investors were waiting for, while BioNTech Se (NASDAQ: BNTX) offers greater financial flexibility and a broader oncology pipeline. The question is whether Moderna's stronger clinical proof deserves its valuation premi...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Phase 3 results leaked Thursday ahead of Saturday’s ESMO presentation, prompting an official release from Moderna and Merck.</li><li>The vaccine-Keytruda combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% versus Keytruda alone.</li><li>Bernstein saw a sell-the-news event, while RBC questioned commercial prospects.</li></ul>Moderna’s (MRNA) cancer-vaccine rally hit a setback on Thursday as shares slid toward their worst week in three months and Mizuho analyst Jared Holz warned that extreme volatility made the stock a “do-not-trade” for many investors.<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> plunged nearly 18% to close at $202.63 on Thursday, its worst session in more than two months. Shares are down 7% for the week, putting them on track for their steepest weekly loss since late July.&nbsp;<h2 class="st-heading-2">Analyst Warns On Moderna, Sees Appeal In Merck</h2>Speaking to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=oCnt-mhxwjU">CNBC</a>, Holz said the decline did not mean the trial results were bad.“And so, I actually don’t think the data were bad at all,” he said. “It was probably just the bar that we sort of create for ourselves on Wall Street was, you know, a little bit too high, and so shares fell.”The analyst also pointed to Moderna’s huge daily price moves as a reason many investors might avoid trading the stock. “That’s why I think, again, for a lot of investors out there, this Moderna is a do-not-trade type of stock because it’s just so volatile,” he said.Investors were also looking for clues about whether the treatment could work beyond melanoma, Holz said. He described a split between investors expecting broad success and those who believe melanoma was the easiest tumor type to show benefit in.“But I’m not sure we learned anything about renal cell, and I’m not sure we learned anything about lung. So we’re just going to have to wait,” he said. Holz identified BioNTech as the other cancer-vaccine developer on his radar. However, for investors bullish on the Moderna-Merck program, he highlighted Merck.“But Merck is actually somewhat compelling here, I think, if you’re actually bullish on the prospects,” he said.<h2 class="st-heading-2">Data Leak Jolts Moderna’s Vaccine Rally</h2>Moderna’s selloff came after a Thursday leak of Phase 3 cancer-vaccine data ahead of Saturday’s ESMO presentation in Madrid. Merck and Moderna subsequently released the official findings for their personalized vaccine, Intismeran Autogene, combined with Keytruda.The trial of over 1,100 patients with surgically removed high-risk melanoma showed a 42% reduction in the relative risk of recurrence or death and a 38% reduction in distant metastasis or death versus Keytruda alone. Overall-survival data is immature but showed a favorable trend, with no new safety signals reported.The topline announcement in August, which withheld numerical results, sparked Moderna’s largest one-day percentage gain on record. Shares also hit a 52-week high of $254.48 on Wednesday ahead of the detailed data release. Earlier this month, Moderna and Merck expanded their collaboration with Tempus to support potential commercialization of the cancer vaccine, while Moderna also joined the Nasdaq-100.The company is seeking growth beyond COVID vaccines after revenue fell to $1.9 billion in 2025 from $3.2 billion in 2024. It targets cash breakeven around 2028 and will report earnings on Nov. 6.<h2 class="st-heading-2">Analysts Weigh A ‘Sell The News’ Reaction</h2>Bernstein called Moderna’s plunge a “sell the news event,” despite a “strong Phase 3 result and meaningful validation of Moderna’s individualized neoantigen platform.” The firm’s 'Market Perform' rating and $45 target imply 78% downside from current levels.&nbsp;TD Cowen saw the initially leaked findings as “compelling” and within the “exceptional range” outlined by key opinion leaders, but said the benefit against distant metastasis fell short of elevated expectations. The firm said the efficacy and safety profile, if confirmed, could support broad adoption, particularly in Stage II melanoma. Its 'Hold' rating and $90 target imply a 56% downside.BMO Capital Markets highlighted the unanswered question of efficacy beyond melanoma. “Investors were looking for these data to demonstrate a benefit in melanoma, but also read into efficacy in other tumors. These results are not enough to drive confidence amidst elevated expectations,” the firm said.Meanwhile, RBC called the findings “materially less impressive” than the earlier trial and questioned the commercial opportunity. “While approval is likely, commercial success is far less certain,” the brokerage said. Wells Fargo, on the other hand, said concerns about Merck’s data “may be overdone,” adding that recurrence-free survival results exceeded investor expectations.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About MRNA And MRK?</h2>On Stocktwits, retail sentiment was ‘bullish’ for both Moderna and Merck, with message volume ‘extremely high’ for Moderna and ‘high’ for Merck.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_e183716434.png" alt="mrna ss.png" width="636" height="344"><figcaption>MRNA sentiment and message volume as of October 22 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RedditUser5/message/667169339">said</a>, “<a href="https://stocktwits.com/symbol/MRNA">$MRNA</a> We should all support what Moderna is doing and recognize that the results published today mark a step forward for humanity.”<stembedurl>https://stocktwits.com/RedditUser5/message/667169339</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Juststartingout14/message/667178650">said</a>, “Keytruda is THE treatment for most cancers...and right now it&nbsp; looks like it will be used together with mRNA vaccine. That is a huge burger.”<stembedurl>https://stocktwits.com/Juststartingout14/message/667178650</stembedurl>While MRNA stock has rocketed 587% year-to-date, MRK fell 43% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/space-x-reportedly-eyes-80-000-cell-sites-in-push-to-become-fourth-us-wireless-carrier-t-tmus-vz-stocks-slip-after-hours/cZxwFlZRBDk">SpaceX Reportedly Eyes 80,000 Cell Sites In Push To Become Fourth US Wireless Carrier: T, TMUS, VZ Stocks Slip After-Hours&nbsp;</a>

In this photo illustration, the American pharmaceutical and biotechnology company Moderna logo is displayed on a smartphone screen. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

iShares Biotechnology ETF

Merck & Co Inc

Moderna Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

BNTX News